Training Together, Diagnosing Better: Federated Learning for Collagen VI–Related Dystrophies
Astrid Brull, Sara Aguti, Véronique Bolduc, Ying Hu, Daniel M. Jimenez-Gutierrez, Enrique Zuazua, Joaquin Del-Rio, Oleksii Sliusarenko, Haiyan Zhou, Francesco Muntoni, Carsten G. Bönnemann, Xabi Uribe-Etxebarria · 2025
Read Training Together, Diagnosing Better: Federated Learning for Collagen VI–Related Dystrophies by Astrid Brull, Sara Aguti, Véronique Bolduc, Ying Hu, Daniel M. Jimenez-Gutierrez, Enrique Zuazua, Joaquin Del-Rio, Oleksii Sliusarenko, Haiyan Zhou, Francesco Muntoni, Carsten G. Bönnemann, Xabi Uribe-Etxebarria (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2512-16876.txt.
Introduction
Astrid Brull and a large international team use federated learning to diagnose collagen VI related dystrophies, a group of rare inherited muscle diseases. Patient data for these diseases are scarce and split across hospitals in many countries, and privacy law blocks pooling the scans in one place.
Federated learning trains one shared model while the data stay at each home site. Two worldwide groups trained on microscopy images of collagen VI taken from patient cell cultures. The joint model sorted the images into three disease mechanism groups and scored well above the models that each site trained alone. The team expects the shared approach to help read gene variants of unclear meaning as well.
Catalog record
| CREATOR | Astrid Brull, Sara Aguti, Véronique Bolduc, Ying Hu, Daniel M. Jimenez-Gutierrez, Enrique Zuazua, Joaquin Del-Rio, Oleksii Sliusarenko, Haiyan Zhou, Francesco Muntoni, Carsten G. Bönnemann, Xabi Uribe-Etxebarria |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2512-16876
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Training Together, Diagnosing Better: Federated Learning for Collagen VI–Related Dystrophies Astrid Brull, Sara Aguti, Véronique Bolduc, Ying Hu, Daniel M. Jimenez-Gutierrez, Enrique Zuazua, Joaquin Del-Rio, Oleksii Sliusarenko, Haiyan Zhou, Francesco Muntoni, Carsten G. Bönnemann, Xabi Uribe-Etxebarria Abstract Abstract The application of Machine Learning (ML) to the diagnosis of rare diseases, such as collagen VI-related dystrophies (COL6-RD), is fundamentally limited by the scarcity and fragmentation of available data. Attempts to expand sampling across hospitals, institutions, or countries with differing regulations face severe privacy, regulatory, and logistical obstacles that are often difficult to overcome. The Federated Learning (FL) provides a promising solution by enabling collaborative model training across decentralized datasets while keeping patient data local and private. Here, we report a novel global FL initiative using the Sherpa.ai FL platform, which leverages FL across distributed datasets in two international organizations for the diagnosis of COL6-RD, using collagen VI immunofluorescence microscopy images from patient-derived fibroblast cultures. Our solution resulted in an ML model capable of classifying collagen VI patient images into the three primary pathogenic mechanism groups associated with COL6-RD: exon skipping, glycine substitution, and pseudoexon insertion. This new approach achieved an F1-score of 0.82, outperforming single-organization models (0.57–0.75). These results demonstrate that FL substantially improves diagnostic utility and generalizability compared to isolated institutional models (see Figure 1 ). Beyond enabling more accurate diagnosis, we anticipate that this approach will support the interpretation of variants of uncertain significance and guide the prioritization of sequencing strategies to identify novel pathogenic variants. Figure 1 : Overview of the Sherpa.ai FL setup showing individual institutional accuracies and the resulting global federated model performance. 1 Introduction Collagen VI is an extracellular matrix (ECM) protein that forms a beaded microfibrillar network surrounding skeletal muscle fibers, contributing to muscle function and myofiber integrity. It is composed of three alpha chains, \alpha 1(VI), \alpha 2(VI) and \alpha 3(VI), encoded by COL6A1, COL6A2 and COL6A3 genes, respectively. The assembly of collagen VI occurs as a highly orchestrated, multistep process: the three alpha chains intertwine into a triple-helical, heterotrimeric monomer, which subsequently dimerizes and assembles into tetramers. Tetramers are secreted into the extracellular space where they associate to form a beaded microfibrillar network. Pathogenic variants in any of the three COL6 genes disrupt collagen VI assembly and function, leading to a spectrum of COL6-related muscular dystrophies, ranging from the mild Bethlem muscular dystrophy (BM), via an intermediate phenotype, to the severe Ullrich congenital muscular dystrophy (UCMD). 4 A diagnosis of collagen VI-related dystrophies (COL6-RD) can be suspected in an individual with characteristic clinical features, muscle imaging features, muscle immunohistochemical features, and collagen VI abnormalities in dermal fibroblast cultures. 12 This initial subjective evaluation is mostly qualitative, and definitive diagnosis relies on the identification of a pathogenic variant in one of the three COL6 genes via molecular genetic testing. However, diagnosis remains challenging despite advances in next-generation sequencing technologies. The complexity of variant identification has increased with the discovery of more intronic variants that retain introns at low levels, complicating the interpretation of genetic data (C.B., unpublished data). Furthermore, there are still many variants of unknown significance, adding another layer of difficulty in making an accurate diagnosis. Although some methods for quantification have been developed 26 , they do not consider the microfibrillar structure that is crucial in assessing the function of collagen VI; therefore, alternative quantitative methodologies to evaluate collagen VI abnormalities are needed. COL6-RD is caused either by recessive loss-of-function variants or, more commonly, by de novo dominant-negative pathogenic variants. Biallelic recessive variants typically result in loss-of-function or nonsense-mediated RNA decay, and are readily identified by collagen VI immunostaining as the collagen VI signal is reduced or absent. Heterozygous dominant-negative variants, in contrast, can be broadly categorized into three main groups based on their pathogenic mechanism: (i) pathogenic variants causing in-frame exon skipping ( e.g. splice site variants, in-frame deletions) in any of the three COL6 genes, (ii) pathogenic variants causing single-amino acid substitutions which disrupt the Gly-X-Y motif of the highly conserved N-terminal triple helical domain of any of the three COL6 genes, and (iii) the recurrent deep-intronic pathogenic variant in intron 11 of COL6A1 gene (c.930+189C > T), which creates a cryptic donor splice site that prompts the insertion of a 72-nt in-frame pseudoexon 4 , 1 , 5 , 3 , 8 , 20 , 11 . De novo dominant-negative pathogenic variants result in the production of structurally abnormal but still assembly-competent alpha-chains. These mutated chains thus retain the ability to assemble into dimers and tetramers but ultimately lead to the deposition of a dysfunctional collagen VI matrix, as revealed by collagen VI immunostaining. Although collagen VI immunostaining of patient-derived fibroblast cultures can detect collagen VI matrix abnormalities, distinguishing among these three groups based on visual inspection remains challenging due to subtle differences in staining patterns (Figure 2 ). Figure 2 : Collagen VI immunofluorescence images from control and patient-derived dermal fibroblast cultures. Each image represents one of the four classes. Scale bar = 50 \mu m. Machine Learning (ML) has become a powerful tool in medical diagnosis and treatment, enabling the identification of complex patterns within biomedical data. However, its successful application in rare diseases research, such as studies involving COL6-RD, is hindered by the limited availability of large and diverse datasets necessary for training accurate and generalizable models. Traditional approaches to data sharing, such as centralized aggregation (Figure 3 Left), consolidate data from multiple sources onto a single server. While this can increase dataset size and heterogeneity, it raises significant concerns regarding privacy, regulatory compliance, and logistical challenges, including compliance with the General Data Protection Regulation (GDPR) 10 , data transmission costs, and restrictions imposed by data localization laws. Figure 3 : Traditional (Centralized) training (left) compared to Federated training implemented on the Sherpa.ai FL platform (right). In FL, only model updates (not raw images) are shared with a central aggregator, enhancing privacy and regulatory compliance. Federated Learning (FL) offers a promising alternative by enabling the training of ML models across distributed institutions (nodes) without sharing raw data (Figure 3 , Right). In FL, each node keeps its data locally and only shares model updates with a central aggregator, which integrates these updates to improve a global model. 25 . This approach enhances data privacy, facilitates regulatory compliance, reduces bandwidth requirements, and allows for the inclusion of diverse, geographically distributed datasets. Despite these advantages, FL still faces several challenges, such as security vulnerabilities, increased communication overhead, and the presence of non-independent and identically distributed (non-IID) data across nodes 22 . In real-world scenarios, non-IID data distributions are common due to variations in patient populations, imaging equipment, and data acquisition protocols. Such heterogeneity can hinder model convergence, reduce performance, and introduce instability or bias during training 18 , 23 . To address these issues, recent research has explored various strategies, including personalization techniques, adaptive aggregation schemes, and robust optimization methods 34 , aimed at improving model performance under non-IID conditions. This study presents a novel multi-institutional FL effort for diagnosing COL6-RD using collagen VI immunofluorescence microscopy images from patient-derived fibroblast cultures. The model was trained on data from 90 COL6-RD patients from two geographically distinct sites across two countries. Specifically, this work describes a new approach to